Loading clinical trials...
Loading clinical trials...
Randomized ph. II Study to Explore Efficacy and Feasibility of Upfront Rotations Between SUNitinib and Everolimus vs Sequential Treatment of 1st lIne Sunitinib & 2nd Line EverolimuS Until Progression in Pats Met. Clear Cell Renal Cancer
Conditions
Interventions
Sunitinib
Everolimus
Locations
10
France
Hopital Bordeaux University
Bordeaux, France
ALEXANDRA General Hospital of Athens
Athens, Greece
Hospital Marqués de Valdecilla
Santander, Cantabria, Spain
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Hospital del Mar
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Start Date
February 12, 2013
Primary Completion Date
May 8, 2017
Completion Date
May 8, 2017
Last Updated
October 2, 2017
NCT06391099
NCT07227415
NCT06835972
NCT07175480
NCT05700461
NCT05122546
Lead Sponsor
Associació per a la Recerca Oncologica, Spain
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions